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Strengths and limitations of this study
 ► This is the first study to include EQ- 5D- 5L, ICECAP- A 
and ICECAP- O in a think- aloud study with people re-
quiring kidney care.
 ► The sample consists of a broad range of people re-
quiring kidney care including renal outpatients for 
chronic kidney disease, kidney transplant check- ups 
and haemodialysis.
 ► Think- aloud studies aim to identify errors and strug-
gles in task completion as they occur.
 ► Five raters, with diverse experience across health 
economics, qualitative research and kidney care, 
identified errors and struggles from the think- aloud 
transcripts.
 ► Think- aloud relies on participants verbalising their 
difficulty in task completion.
AbStrACt
Objectives To determine the response process validity, 
feasibility of completion, acceptability and preferences for 
three patient- reported outcome measures that could be 
used in economic evaluation—the EQ- 5D- 5L, ICECAP- A 
and ICECAP- O—in people requiring kidney care.
Design Participants were asked to ‘think- aloud’ while 
completing the EQ- 5D- 5L, ICECAP- A and ICECAP- O, 
followed by a semistructured interview. Five raters 
identified errors or struggles in completing the measures 
from the think- aloud component of the transcripts. 
Patient preferences for measures were extracted from the 
semistructured interview.
Setting Eligible patients were identified through a large 
UK secondary care renal centre.
Participants In total, 30 participants were included in the 
study, consisting of patients attending renal outpatients 
for chronic kidney disease (n=18), with a functioning 
kidney transplant (n=6) and receiving haemodialysis 
(n=6).
results Participants had few errors and struggles in 
completing the EQ- 5D- 5L (11% error rate, 3% struggle 
rate), ICECAP- A (2% error rate, 2% struggle rate) and 
ICECAP- O (4% error rate, 3% struggle rate). The main 
errors with the EQ- 5D- 5L were judgements that did 
not comply with the ‘your health today’ instruction. 
Comprehension errors were most prominent on ICECAP- O. 
Judgement errors were the only errors reported on 
ICECAP- A. Although the EQ- 5D- 5L had slightly more errors 
and struggles, it was the measure most preferred, with 
participants able to make a clearer link with EQ- 5D- 5L and 
their health condition.
Conclusions The EQ- 5D- 5L, ICECAP- A and ICECAP- O 
are feasible for people requiring kidney care to complete 
and can be included in studies conducting economic 
evaluations of kidney care interventions. Further research 
is required to assess how health (eg, EQ- 5D) and capability 
(eg, ICECAP) measures can be included in an economic 
evaluation simultaneously, as well as what ICECAP 
measure(s) to include when patient groups straddle 
the age ranges for ICECAP- A (18 years and older) and 
ICECAP- O (65 years and older).
bACkgrOunD
Healthcare expenditure is rising globally 
and has been increasing at a faster rate than 
international economic growth over the past 
decade.1 Chronic kidney disease (CKD) is a 
growing burden on healthcare resources. In 
the 2015 Global Burden of Disease Study,2 
CKD were the 12th leading cause of death and 
17th leading cause of global life years lost.3 In 
the UK alone, CKD accounts for more than 
one per cent of the National Health Service 
(NHS) annual budget.4 Given this volume of 
expenditure, it is important that any health-
care resources allocated to managing kidney 
problems are used efficiently.
To determine which interventions should 
be recommended for practice, economic 
evaluations provide evidence on cost- 
effectiveness by comparing the costs and 
benefits of alternative interventions. In health 
and care, these economic evaluations increas-
ingly rely on patient- reported outcome 
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measures (PROMs) to capture the health- related quality 
of life improvements from interventions5 and are recom-
mended for the generation of quality adjusted life years 
(QALYs) internationally.6 A QALY is a combination of life 
years adjusted for health- related quality of life.7 Choice 
of PROM in generating QALYs plays an influential role 
in deciding if a treatment is cost- effective.8 9 The EQ- 5D 
is the most widely used measure to calculate QALYs in 
economic evaluations internationally5 and has been trans-
lated into 169 different languages.10 The EQ- 5D has also 
been separately recommended by an expert consensus 
for routine collection across European renal registries.11
Despite international recommended use of QALYs in 
healthcare, the suitability of this outcome is debated, 
partly due to the exclusive focus on health gains and 
not broader well- being.7 12 13 An alternative approach 
has been proposed to capture broader well- being, which 
focuses on a person’s capabilities, meaning a person’s 
freedom to achieve the things in life that are valuable 
to them.14 Health bodies in the UK and the Nether-
lands have recognised the limitation of relying purely 
on QALYs in social care15 and long- term health condi-
tions.16 Capability measures, such as the ICECAP- A17 (A—
all adults aged 18 years and above) and the ICECAP- O 
(O—older adults aged 65 years and above),18 have been 
recommended as ways to capture the broader benefits 
for these patient groups. It is not entirely clear, however, 
which ICECAP measure to use when the age range of a 
patient group could use either ICECAP- A or ICECAP- O. 
People requiring kidney care are a prime example of this 
challenge, with the median age for starting renal replace-
ment therapy in the UK being 64 years of age in 2017.19 A 
recent study found the ICECAP- O to be a valid measure in 
over 75- year- old patients receiving dialysis or conservative 
care for end- stage kidney disease (ESKD).20 ICECAP- O 
was also developed first and has been shown to be a 
valid outcome in older and younger adults in different 
settings.21 However, no previous study has tested the 
ICECAP- A and ICECAP- O in the same patient group.21
The objective of this study was to (1) assess response 
process validity, feasibility of completion and acceptability 
of the health- related quality of life PROM EQ- 5D- 5L, and 
two capability PROMs of broader well- being, ICECAP- A 
and ICECAP- O, in patients requiring kidney care, and (2) 
assess patient preferences for the three PROMs.
MethODS
This research consists of a ‘think- aloud’ study followed 
by a semistructured interview. A think- aloud study is 
a cognitive interview method whereby individuals are 
asked to verbalise their thought process when completing 
measures.22 Think- aloud interviews enable the exam-
ination of problems patients may encounter in terms 
of comprehension, retrieval, judgement and response 
difficulties. The interviewer remains silent, so long as 
individuals continue to think- aloud. This process is 
thought to give a more realistic picture of the problems 
that individuals face when completing questionnaires 
than more direct interview methods that interrupt task 
completion.23 Think- aloud interviews are a method that 
allow for the assessment of validity in terms of investi-
gating response processes.24 Assessing response processes 
is one of five recommended sources of validity evidence.25
Sampling and recruitment
Samples for previous think- aloud studies on health and 
capability PROMs have ranged from 1026 to 3427 partic-
ipants. Based on these previous studies, saturation 
(whereby no new insights would be anticipated from 
additional sampling)28 was expected to be reached at 25 
participants here.
Patients were recruited through a large UK secondary 
care renal centre. Participants were sampled purpose-
fully to achieve diversity in age (classified as <65 or 
≥65) and type of kidney care received, but in line with 
general approaches to sampling in qualitative research, 
sampling did not aim for representativeness.28 Sampling 
was conducted through renal outpatient lists and a dial-
ysis unit. Eligibility required individuals to have CKD, be 
willing and able to provide informed consent to partic-
ipate, and be able to communicate in English (because 
the study was exploring the use of English language ques-
tionnaires). Potential participants received a participant 
information sheet (PIS— see online supplementary file 
2) in the post or at the dialysis unit and were invited to 
take part via a follow- up telephone call from a clinical 
trials officer. The PIS was the only information provided 
to the participant about the researcher prior to interview.
Instruments investigated
The EQ- 5D- 5L consists of five dimensions of health status 
covering mobility, self- care, usual activities, pain/discom-
fort and anxiety/depression across five levels ranging 
from no problems to extreme problems.29 The EQ- 5D- 5L 
was introduced to supersede the EQ- 5D- 3L to reduce 
ceiling effects and increase sensitivity to change, by 
moving from a three- level to a five- level severity measure 
of health problems, but with the same five dimensions. 
A Visual Analogue Scale (VAS) is also included that 
asks respondents to rate their health today on a 0–100 
scale from worst to best imaginable health state. The 
National Institute for Health and Care Excellence in 
England recommends the collection of the EQ- 5D- 5L for 
conducting health economic evaluation.30
The ICECAP- A is a capability well- being measure devel-
oped for the general adult population (ie, all adults, 
including those aged over 65).17 It consists of five dimen-
sions relating to a person’s capability to have attachment, 
stability, achievement, enjoyment and autonomy. Each 
dimension has four levels ranging from no capability to 
full capability. The capabilities were identified through 
qualitative research with members of the general public 
aged 18 years and above (including over 65 year olds) to 
identify what was most important to them in their life.17
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The ICECAP- O is a capability well- being measure devel-
oped for older adults.18 The ICECAP- O was the first of 
the ICECAP suite of measures developed that aimed to 
develop a more appropriate quality of life measure for 
older adults specifically for use in the economic eval-
uation of health and care interventions.31 It consists of 
five dimensions relating to a person’s capability to have 
attachment, security, role, enjoyment and control. Each 
dimension has four levels ranging from no capability to 
full capability. As with the ICECAP- A, the capabilities 
were identified through qualitative research, but in this 
case with older members of the general public aged 65 
years and above.32
Data collection
Once participants had provided informed consent, inter-
views took place at the renal centre or in the participant’s 
home. All interviews were conducted by PM, a male PhD 
researcher in health economics with qualitative inter-
view training and an interest in PROMs research. Initial 
questions focused on basic sociodemographic infor-
mation. Participants then completed a simple warm- up 
task to determine the number of windows in their 
home. A second warm up task involved the completion 
of the Global Quality of Life scale.33 Participants then 
completed the think- aloud exercise. They were allo-
cated sequentially to receive ICECAP- A or ICECAP- O 
first or third, with EQ- 5D- 5L (including the EQ- VAS) 
always completed second; given the similarities between 
ICECAP- A and ICECAP- O, it was seen as a stronger design 
to separate these two measures to avoid confusion. Partic-
ipants were not interrupted during the completion of the 
three measures unless they were silent for longer than 
10 seconds when they were asked to ‘keep thinking aloud’. 
Following the think- aloud task, a semistructured inter-
view was conducted to clarify issues arising in the think- 
aloud task and to explore views about the three measures. 
Field notes were made during the think- aloud compo-
nent to guide the semistructured interview. The interview 
guide was piloted prior to interview. Transcripts were not 
returned to participants for comment and/or correction 
and they did not provide feedback on the study findings. 
Repeat interviews were not carried out. Interviews were 
audio recorded and transcribed verbatim. Data were 
managed in Microsoft Word and Excel.
Data analysis
Think-aloud analysis
The think- aloud section from each transcript was extracted 
for each of the measures and divided into 16 segments: 6 
representing the items on the EQ- 5D- 5L (including the 
EQ- 5D- VAS), 5 items on the ICECAP- A and ICECAP- O, 
respectively. Think- aloud sections of the interview, along-
side the reported response level for each item on each 
measure, were presented to five independent raters (PM, 
FC, JS, SS and JC), with expertise in health economics (PM, 
SS and JC), qualitative research (JC) and renal care (FC 
and JS). Each rater individually examined all think- aloud 
sections to identify problems participants encountered 
when completing each of the three measures. Raters were 
asked to identify whether responses were error free or 
contained any of the following problems, based on the 
survey response model34:
1. Comprehension error (understanding the question in 
the way the researcher intended).
2. Retrieval error (retrieving appropriate information 
from their long- term memory).
3. Judgement error (correctly judging how recalled infor-
mation should be used to answer).
4. Response error (format the information into a valid 
response for the questionnaire).
5. Struggle (not one of the four errors but clear difficulty 
in answering the question).27
Following these independent ratings, each item was 
identified as error free, containing an error or containing 
a struggle, using the following rules:
 ► Where three or more raters identified a specific error/
struggle, it was classed as an error/struggle.
 ► Where one or none thought an error was present, it 
was marked as error free.
 ► Where two or more raters identified an error/
struggle but there was no majority agreement on the 
type of error/struggle, a decision was made during a 
consensus meeting with all raters; a majority decision 
was used when no consensus occurred.
Consistency between raters on the coding of the data 
was assessed using raw agreement and a weighted kappa 
statistic.35 For the latter, where an error and no error were 
reported between raters, this was weighted as 0; all other 
disagreements—such as different error types, error/
struggle or struggle/no error—was weighted as 0.5, with 
agreement weighted as 1.
Preference between measures
During the semistructured interviews following the think- 
aloud task, individual preferences for completing the 
three measures were explored. Individuals were asked 
which of the three measures they preferred and why they 
thought it was more important in assessing their quality 
of life.
Patient and public involvement
Patients and the public were not directly involved in the 
design of the study.
reSultS
Three hundred and thirty- four patients were invited to 
take part in the study. Of these, 161 responded to tele-
phone follow- up and 37 agreed to participate. In four 
cases, patients did not attend the interview, one indi-
vidual was too unwell to participate and one decided 
against participation during the consent process. Thir-
ty- one individuals took part, but one individual did not 
understand the task (reading aloud their response levels 
only), leaving 30 individuals as the final sample. Most 
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Table 1 Participants’ characteristics (n=30)
Sex
  Male 23
  Female 7
Ethnicity
  White 28
  Non- white 2
Age group
  75+ 4
  65–74 8
  55–64 7
  45–54 6
  35–44 4
  18–34 1
Kidney care received
  Renal outpatients 18
  Renal outpatients (transplant) 6
  Dialysis 6
interviews took place at the healthcare facility, with four 
taking place in the participant’s home. Most interviews 
were conducted one- to- one; on occasion at the health-
care facility patients’ partners were present. Interviews 
were conducted between April and July 2017 and lasted 
between 16 and 55 min (average 33 min). Characteristics 
of the sample are presented in table 1.
think-aloud analysis: errors and struggles
Following independent coding of the think- aloud inter-
views by five raters, inter- rater agreement was similar 
for ICECAP- A (85%–95%) and ICECAP- O (83%–93%), 
slightly lower for EQ- 5D- 5L (78%–84%) and weighted 
chance- corrected agreement being rated ‘fair’ to 
‘moderate’ for 29 out of 30 inter- rater comparisons using 
standard guidelines.36 Eight errors (four EQ- 5D- 5L, zero 
ICECAP- A and four ICECAP- O), eight struggles (five 
EQ- 5D- 5L, one ICECAP- A and two ICECAP- O) and 52 
possible error/struggles were identified through inde-
pendent rating. At the subsequent rater meeting, from 
the 52 possible error/struggles, a further 26 errors or 
struggles were agreed on: 17 of 29 for the EQ- 5D- 5L, 5 
of 11 for the ICECAP- A and 4 of 12 for the ICECAP- O. 
Breakdowns of error type by measure item are reported 
in tables 2–4.
In total, 179 segments were generated for the EQ- 5D- 5L 
(one VAS was not completed by accident) and 150 
segments each for the ICECAP- A and ICECAP- O. Twenty 
(11%) out of the 179 segments of the EQ- 5D- 5L were asso-
ciated with an error and six (3%) with a struggle. Three 
(2%) out of the 150 segments of the ICECAP- A were asso-
ciated with an error and three (2%) with a struggle. Six 
(4%) out of the 150 segments of the ICECAP- O were asso-
ciated with an error and four (3%) with a struggle.
The majority of responses were not identified as an 
error or struggle on any of the three measures, indicating 
feasibility of use for all three PROMs. Participants found 
all measures easy to complete overall, showing accept-
ability in completing these PROMs:
Very straightforward. (Participant 26, male, aged 65–
74, dialysis patient)
Not particularly, they all seemed, they’re all pretty 
relevant to the questionnaire and to my condition 
and recovery and all that sort of thing so nothing sort 
of surprised me what was being asked so, happy with 
all the questions that was fine. (Participant 21, male, 
18–35, kidney transplant outpatient)
There were more errors (17) and struggles (4) reported 
for EQ- 5D- 5L (even when excluding the EQ- VAS) than 
for either ICECAP measure. The most common error 
type for EQ- 5D- 5L related to judgement, with this error 
recorded at least once across all EQ- 5D- 5L dimensions. 
Raters decided that a judgement error had occurred 
when participants clearly diverged from the EQ- 5D- 5L 
instruction to focus on ‘your health today’:
I am working – I am doing this on – on a bad day. 
(Participant 19, male, aged 55–64, judgement errors 
for four of five EQ- 5D- 5L dimensions)
Response errors for the pain/discomfort dimension 
were driven by the infrequency with which they were 
reported to occur:
But sitting here now I would put my state, a little bit 
of discomfort, but I don’t think either end of the 
spectrum really indicates what I actually feel. Because 
it is a thing which either comes on and then is put 
right by antibiotics or painkillers, so I’m going to 
put moderate pain or discomfort. But perhaps there 
should be a box for occasional to indicate recurrent 
or occasional pain. (Participant 12, male, aged 65–74, 
pain/discomfort response error)
Response errors for usual activities were due to no 
response being provided and one participant felt that 
their true response was in between slight and moderate 
problems. The only other error recorded on the EQ- 5D- 5L 
was also for usual activities in terms of comprehension:
Not sure what my usual activities are. Walking I sup-
pose. I’m sorry I can’t think what my usual activities 
are. So I don’t know what to put there. (Participant 
27, male, aged 75+, usual activities response error)
For the ICECAP- A, there were only judgement errors 
or struggles reported. The attachment and enjoyment 
dimensions were error and struggle free. Two of the 
judgement errors follow a similar pattern as for EQ- 5D, 
where one individual reported their capability on a bad 
day, rather than at the moment. The other judgement 
error related to the participant's interpretation of the 
item:
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Table 2 Errors and struggles: EQ- 5D- 5L (n=30)






  Comprehension 0 0 1 0 0 0 1
  Retrieval 0 0 0 0 0 0 0
  Judgement 1 1 2 6 2 2 14
  Response 0 0 2 2 0 1 5
Struggle 1 0 1 2 0 2 6
Total 2 1 6 10 2 5 26
*n=29.
VAS, Visual Analogue Scale.
Table 3 Errors and struggles: ICECAP- A (n=30)
Stability Attachment Autonomy Achievement Enjoyment Total
Error
  Comprehension 0 0 0 0 0 0
  Retrieval 0 0 0 0 0 0
  Judgement 0 0 2 1 0 3
  Response 0 0 0 0 0 0
Struggle 2 0 0 1 0 3
Total 2 0 2 2 0 6
… I’m reading that one as being completely indepen-
dent, is that I would probably be quite happy living 
on my own rather than with a partner or family… 
(Participant 10, male, aged 65–74, judgement error)
Comprehension errors were the highest error type for 
ICECAP- O, with two participants unable to understand 
the role dimension and one participant the attachment 
attribute:
Question one, love and friendship, reading the sup-
posed answers, I find them rather confusing. I can 
have all of the love and friendship that I want (-) not 
really [sure] what the question is asking. Very diffi-
cult. Totally bemused by question one, so I will hazard 
a guess. (Participant 8, male, aged 55–64, attachment 
comprehension error)
I don’t want to feel valued. Again I don’t understand 
what this means really. Valued by whom? (-) I don’t 
know I can’t answer that at all. (Participant 27, male, 
aged 75+, role comprehension error)
Another error on the role attribute was found when 
one participant focused on functioning (ie, what they do) 
rather than their capability (ie, what they are able to do):
Yeah, actually, it’s interesting if I think about it a bit 
more actually. I probably am able to do all of the 
things that make me feel valued but don’t actually 
do them. I think I’ll leave that to many of the things. 
(Participant 10, male, aged 65–74, role judgement 
error)
There were two response errors on the enjoyment 
attribute where both individuals felt they were in between 
the same two levels:
…don’t have all the time that I’d like to spend doing 
stuff outside the work so my answer’s probably a two 
and a half but I’ll put a three. (Participant 16, male, 
aged 55–64, enjoyment response error)
Enjoyment and pleasure? I think I’m somewhere – 
I’m gonna put myself unhelpfully at two and a half 
because I don’t think I have a little, I don’t think I 
have a lot. (Participant 18, male, aged 35–44, enjoy-
ment response error)
Measure preferences
The EQ- 5D- 5L was most preferred (n=17), five preferred 
ICECAP- O, three preferred ICECAP- A and five were 
unable to make a choice. One reason for preferring 
EQ- 5D- 5L was that participants could more clearly see the 
connection between the questions being asked and their 
illness:
I think the one that…because I’ve come via the kidney 
clinic, I’m- I’m thinking that this kidney research rath-
er than general life research, so I think the one that 
relates most clearly to health and different problems 
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Table 4 Errors and struggles: ICECAP- O (n=30)
Attachment Security Role Enjoyment Control Total
Error
  Comprehension 1 0 2 0 0 3
  Retrieval 0 0 0 0 0 0
  Judgement 0 0 1 0 0 1
  Response 0 0 0 2 0 2
Struggle 1 1 2 0 0 4
Total 2 1 5 2 0 10
that you might experience with kidney problems… is 
(EQ- 5D- 5L). (Participant 5, female, aged 45–54)
That one about the physical thing. That seemed to 
be more relevant about whether you're well, ill or 
what other problems you've got. More relevant for a 
medical questionnaire rather than how you feel and 
stuff. But I know how you feel is important as well but 
you know, whether you can get about and might need 
help getting to appointments, things like that might 
be more, more relevant. (Participant 17, male, aged 
35–44)
Reasons for preferring either ICECAP measure were 
due to what was being measured and a perceived greater 
depth compared with the EQ- 5D- 5L:
That one’s (EQ- 5D- 5L) really quite a superficial, can 
I walk around, can I wash myself, kind of very opera-
tional stuff. These two are more about kind of more 
psychological as well as quite physical things. Other 
than you talk about anxiety, depression there and I 
instantly said I don’t – clearly they’re in my head I’m 
not depressed, I don’t have that illness. I would – so 
would put down to these two and I would go with 
this one (ICECAP- A) because I quite like the – the 
independent, achievement and progress but I think 
that one was a brilliant question because I think that’s 
probably the most important thing that is on my mind 
at the moment. (Participant 18, male, aged 35–44)
Because (ICECAP- O) thats… it’s all embodying isn't 
it about your family, your life, what you do, where 
you think you’re going. (Participant 15, male, aged 
65–74)
DISCuSSIOn
This study explored the response process validity, feasibility 
of completion and acceptability of EQ- 5D- 5L, ICECAP- A 
and ICECAP- O in patients requiring kidney care and 
preferences between the three PROMs. There were more 
errors and struggles reported with the EQ- 5D- 5L, mainly 
related to judgement errors with respect to the answer 
provided varying from the measure recall period ‘your 
health today’. Nevertheless, most participants preferred 
the EQ- 5D- 5L for reasons of ease of completion and were 
more directly able to link the wording of the questions to 
their health condition. ICECAP- A had the fewest errors 
and struggles overall. One in six participants or more 
recorded an error or struggle in completing EQ- 5D- 5L 
pain/discomfort, EQ- 5D- 5L usual activities, EQ- 5D- 5L 
VAS and ICECAP- O role items.
This study is the first to collect both ICECAP- A and 
ICECAP- O measures simultaneously from the same popu-
lation. The study benefits from having participants with a 
broad range of kidney problems and receiving different 
treatments. The heterogeneity of the sample in terms of 
age and treatment type means that the findings in this 
study could be applied to other similar settings. There are 
some limitations, however: the sample was predominantly 
male and of white ethnicity. Although most respondents 
were male, this is not dissimilar to renal replacement 
therapy recipients in the UK where almost two in every 
three patients (64.1%) are male.19 Nevertheless, the find-
ings need to be interpreted in light of the sample. In 
addition, the sample does not include patients receiving 
peritoneal dialysis or conservative care for ESKD. The 
think- aloud interview method also relies on participants 
verbalising their difficulty in task completion, so difficul-
ties in completion that the participants did not or were 
not able to express are not captured here.
As with other similar size studies in different popula-
tions, this work has shown that responses to the ICECAP- A 
measure have fewer errors or struggles than those to 
EQ- 5D.27 37 It differs from the only existing comparison 
between EQ- 5D- 5L and ICECAP- O which, in a smaller 
study (n=10) found the EQ- 5D- 5L produced fewer errors 
in completion.26 Errors associated with comprehending 
the attachment and role items on ICECAP- O are similar to 
previous think- aloud studies.26 38 A potential concern over 
the use of the new EQ- 5D- 5L is the number of judgement 
errors that were found here. This seems to be particularly 
related to the prevalence of intermittent health problems 
for people requiring kidney care, which caused patients 
difficulty in responding particularly for the pain/discom-
fort dimension.
The findings suggest that all three measures are appro-
priate for use in people requiring kidney care, with low 
errors and struggles across all measures reflecting the feasi-
bility and acceptability of the three PROMs in this sample. 
However, the three PROMs have different strengths and 
weaknesses; the fewer errors reported for the two ICECAP 
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measures may be traded against the patients’ prefer-
ences for the EQ- 5D- 5L. Indeed, the finding that the 
EQ- 5D- 5L was preferred by patients reflects earlier works 
showing that patients preferred EQ- 5D over a number of 
other condition- specific and generic measures of health 
status.11 For ICECAP measures, the ICECAP- A produced 
fewest errors across this population requiring kidney care 
covering a wide range of ages, but a recent study specif-
ically aimed at over 75 year olds requiring treatment for 
ESKD found ICECAP- O to be a valid outcome.20
From a health and care decision- making point of view, 
although both errors in completion and patient prefer-
ences are important in choice of measure, they are unlikely 
to be the only considerations for choice of measure to 
aid in resource allocation decisions across health and 
care service provision. In a recent review of EQ- 5D scores 
(ie, using population preferences to value the relative 
importance of health states7) attached to health states for 
calculating QALYs in patients with ESKD, there is only 
a clear benefit attached to the health gain from kidney 
transplantation compared with other treatments, such 
as dialysis and conservative care.39 This finding may not 
be surprising given health levels for people with kidney 
transplants have found to be comparable with that of 
the general population40 and is generally considered 
the clinical ‘gold standard’ treatment option for people 
with ESKD.41 However, what may be surprising is that the 
EQ- 5D is not able to distinguish patient benefits from the 
type of dialysis, how dialysis is delivered or whether dial-
ysis is delivered at all. Previous stated preference research 
from Australia has shown that pre- dialysis patients would 
be willing to trade- off on average 7 months of survival 
time to reduce the number of trips to hospital for dial-
ysis per week and on average 15 months of survival time 
to reduce their restrictions on their ability to travel and 
make short trips.42 Such important considerations do not 
appear to be captured using the current economic toolkit 
that focus primarily on patient health status and not the 
impact of that treatment on their broader ability to do 
and be things in life that matter to them.
Future work could look at how decision makers can 
use health and capability measures simultaneously in 
an economic evaluation. In particular for kidney care, 
areas where capabilities might differ most from health 
measures like EQ- 5D could be in areas where dialysis is 
delivered outside of a healthcare facility (ie, peritoneal 
dialysis or home- based haemodialysis) or not delivered at 
all (ie, conservative care). This study also highlights issues 
surrounding the variation in interpretation and judge-
ments relating to the framing of EQ- 5D (ie, ‘your health 
today’) and is likely to be of interest to explore further.43
Further research is required to better understand 
whether the different ICECAP measures are completed 
differently depending on the respondents’ stage of life. 
Measuring capability at different stages across the life 
course may provide an alternative framework for using the 
ICECAP capability measures in economic evaluations for 
health and care interventions.44 More detailed qualitative 
analysis of think- aloud and semistructured interviews may 
provide some answers in the implementation of such a 
life- course framework.
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